Can I Take Saw Palmetto with Egrifta (Tesamorelin)?

How Tesamorelin Works

Tesamorelin is a synthetic 44-amino-acid growth hormone-releasing hormone (GHRH) analog approved by the FDA in 2010 for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It binds pituitary GHRH receptors, triggering a pulsatile release of endogenous growth hormone (GH), which in turn raises circulating insulin-like growth factor-1 (IGF-1) levels.

Pharmacokinetics of Tesamorelin

Tesamorelin is administered as a once-daily subcutaneous injection at 2 mg. Peak plasma concentration occurs roughly 15 minutes post-injection, and the terminal half-life is approximately 26 minutes, reflecting rapid enzymatic proteolysis typical of peptide hormones. Because it is degraded by circulating peptidases rather than hepatic cytochrome P450 enzymes, tesamorelin carries a low risk of classic drug-drug interactions at the CYP level (FDA Egrifta prescribing information).

Clinical Trial Basis

In two Phase III trials (N = 816 combined), tesamorelin 2 mg daily reduced visceral adipose tissue by approximately 15% at 26 weeks compared with placebo, as measured by CT scan. GH and IGF-1 rose predictably, and the most common adverse effects were injection-site reactions (reported in roughly 8.5% of patients), arthralgia, and peripheral edema (Falutz J et al., N Engl J Med, 2007). Those trials did not exclude patients taking common supplements, but saw palmetto use was not tracked as a separate variable.

How Saw Palmetto Works

Saw palmetto (Serenoa repens) is a liposterolic extract widely used for benign prostatic hyperplasia (BPH) symptoms. Its primary pharmacologic actions are partial inhibition of 5-alpha-reductase types I and II (the enzyme converting testosterone to dihydrotestosterone) and mild inhibition of cyclooxygenase (COX), which gives it weak antiplatelet and anti-inflammatory properties.

5-Alpha-Reductase Inhibition

The degree of 5-alpha-reductase blockade from standard-dose saw palmetto (320 mg/day of liposterolic extract) is modest compared with prescription agents like finasteride or dutasteride. A Cochrane systematic review (N = 5,666 across 32 trials) concluded that saw palmetto did not significantly reduce prostate size or improve validated symptom scores versus placebo, suggesting limited systemic hormonal impact at over-the-counter doses (Tacklind J et al., Cochrane Database Syst Rev, 2012).

Anticoagulant and Antiplatelet Properties

Case reports have described rare bleeding events in patients taking saw palmetto, and in-vitro data suggest COX-1 inhibition by fatty acid constituents of the extract. A systematic review of adverse events found that clinically significant bleeding is uncommon but has been reported in patients co-administered anticoagulants or antiplatelet drugs (Agbabiaka TB et al., Drug Saf, 2009). This is relevant to any multi-drug regimen, though tesamorelin itself carries no known anticoagulant effect.

Is There a Direct Interaction?

No. There is no published pharmacokinetic or pharmacodynamic interaction between tesamorelin and saw palmetto in PubMed, the Natural Medicines Comprehensive Database, or the FDA Adverse Event Reporting System (FAERS) as of May 2026.

Why No Pharmacokinetic Conflict Exists

Tesamorelin is a peptide degraded by circulating proteases, not by CYP enzymes. Saw palmetto's liposterolic compounds undergo hepatic CYP-mediated metabolism (primarily CYP2D6 and CYP3A4), but they exhibit negligible inhibitory or inducing effects on those isoforms at standard 320 mg/day doses (Markowitz JS et al., J Clin Pharmacol, 2003). Because tesamorelin bypasses the CYP system entirely, even a theoretical CYP interaction from saw palmetto would be irrelevant.

Why No Direct Pharmacodynamic Conflict Exists

Tesamorelin stimulates the GHRH receptor. Saw palmetto inhibits 5-alpha-reductase. These are separate axes. Tesamorelin raises GH and IGF-1. Saw palmetto mildly reduces DHT without altering GH secretion. No shared receptor, transporter, or signaling cascade has been identified.

Indirect Hormonal Considerations

While no direct interaction exists, both agents touch the broader hormonal environment. Clinicians monitoring a patient on tesamorelin should be aware of how saw palmetto may affect lab interpretation.

IGF-1 Monitoring

Tesamorelin raises IGF-1, and prescribers typically check IGF-1 levels at baseline, 3 months, and periodically thereafter. The FDA label advises discontinuation if IGF-1 exceeds 3 standard deviations above the age-adjusted mean. Saw palmetto has not been shown to independently affect IGF-1 levels. One small study (N = 40) in men with BPH found no significant change in serum IGF-1 after 6 months of saw palmetto 320 mg daily (Marks LS et al., J Urol, 2001). This means saw palmetto is unlikely to confound IGF-1 monitoring.

PSA and Androgen Markers

Saw palmetto can reduce serum PSA by approximately 10-15% in some men, although data are inconsistent. The Cochrane review found no statistically significant PSA reduction versus placebo across pooled data. If a clinician is using PSA trends to monitor prostate health in a male patient receiving tesamorelin (which raises GH and indirectly influences tissue growth factors), concurrent saw palmetto could theoretically mask a PSA rise. This effect is far less pronounced than the 50% PSA reduction seen with finasteride 5 mg, but it warrants disclosure to the prescriber.

Glucose Metabolism

Tesamorelin can raise fasting glucose and HbA1c through GH-mediated insulin antagonism. In Phase III data, mean fasting glucose increased by approximately 3 mg/dL versus placebo (Falutz J et al., JAMA, 2010). Saw palmetto has no established effect on glucose metabolism. This means it will not worsen or improve the glycemic shift from Egrifta, but patients with HIV-associated lipodystrophy often have pre-existing insulin resistance, so glucose monitoring remains standard regardless of supplement use.

Anticoagulant Safety in the Combination

Tesamorelin does not affect platelet function or the coagulation cascade. Saw palmetto's antiplatelet activity is weak and clinically insignificant in isolation at standard doses.

When It Matters

The concern escalates only when other anticoagulants or antiplatelets are in the regimen. Patients with HIV frequently take medications that affect bleeding risk. If a patient is on aspirin, clopidogrel, or a direct oral anticoagulant alongside both Egrifta and saw palmetto, the prescriber should be informed about the saw palmetto component. The FDA Egrifta label does not list any bleeding-related warnings, but a comprehensive medication reconciliation benefits every patient on multi-drug therapy.

Practical Bleeding Risk

A 2009 systematic safety review of saw palmetto identified only two case reports of clinically significant bleeding attributable to the supplement, both in patients on concurrent anticoagulant therapy (Agbabiaka TB et al., Drug Saf, 2009). For a patient taking only tesamorelin and saw palmetto with no other bleeding-risk medications, the antiplatelet concern is minimal.

Dose-Separation and Timing

Because no pharmacokinetic interaction exists, there is no strict requirement to separate doses. Some clinicians recommend a general 1-2 hour buffer between subcutaneous peptide injections and oral supplements to minimize any GI-related variables, but this is a conservative practice rather than an evidence-based mandate.

Suggested Routine

Tesamorelin is typically injected subcutaneously in the abdomen at the same time each day, often in the evening or before bed to align with natural nocturnal GH pulsatility. Saw palmetto 320 mg is usually taken once daily with food to improve absorption of its lipophilic constituents. Taking saw palmetto with breakfast or lunch and injecting tesamorelin in the evening creates a natural time gap without requiring a rigid separation protocol.

If You Miss a Dose

Missing a dose of tesamorelin should be managed per prescribing instructions (skip the missed dose, inject the next dose at the scheduled time). Missing a saw palmetto dose has no acute consequences. There is no rebound or withdrawal effect from either agent, and no interaction-driven reason to adjust one if the other is skipped.

Who Should Be More Cautious

Not every patient on this combination needs extra vigilance. Certain subgroups warrant closer attention.

Patients on Anticoagulant Therapy

As discussed, saw palmetto's mild COX-inhibitory activity becomes more relevant when layered onto an existing anticoagulant regimen. Patients on warfarin in particular should have INR checked after adding or stopping saw palmetto, as case reports have documented INR fluctuation (Beckert BW et al., J Am Acad Dermatol, 2007).

Patients with Active Malignancy

The Egrifta label contraindicates use in patients with active malignancy due to the theoretical risk that elevated GH and IGF-1 could promote tumor growth. Saw palmetto does not share this concern, but any patient with active cancer should not be on tesamorelin regardless of supplement use.

Patients with Impaired Glucose Tolerance

HIV-associated lipodystrophy frequently co-occurs with insulin resistance and metabolic syndrome. Tesamorelin's GH-mediated glucose elevation is modest but real. Saw palmetto does not affect glucose, but patients with pre-diabetes or diabetes should have HbA1c monitored every 3 months during Egrifta therapy as standard of care, as recommended in the FDA labeling (FDA Egrifta prescribing information).

What to Do If You Are Already Taking Both

If you are currently using tesamorelin and saw palmetto together, there is no reason for alarm or immediate discontinuation of either.

Step 1: Inform Your Prescriber

Your HIV or endocrinology provider should know about all supplements, including saw palmetto. This allows them to interpret lab values (especially PSA and IGF-1) correctly.

Step 2: Continue Standard Monitoring

Routine monitoring for tesamorelin includes IGF-1 (baseline and periodically), fasting glucose or HbA1c, and assessment of visceral adipose tissue response. Saw palmetto does not require specific lab monitoring at standard doses, but if you are male and tracking PSA, note that saw palmetto may modestly reduce readings.

Step 3: Watch for Unusual Bleeding

This applies only if you are also on anticoagulant or antiplatelet therapy. Report unexplained bruising, prolonged bleeding from cuts, or blood in stool or urine.

The Bottom Line on Safety

The combination of tesamorelin and saw palmetto has no documented interaction in any published database. Tesamorelin is a subcutaneous peptide degraded by proteolysis, not CYP450 metabolism. Saw palmetto is a liposterolic oral supplement with limited systemic hormonal effects at standard doses. The two agents do not share receptors, enzymes, or transporters. Indirect effects on lab markers (PSA, IGF-1) are minor and manageable through routine prescriber communication.

The Endocrine Society's 2019 clinical practice guideline on GH use in adults does not address saw palmetto specifically but recommends that all patients on GH-axis therapy disclose supplement use to their managing clinician (Fleseriu M et al., J Clin Endocrinol Metab, 2019). That standard applies here. Tell your doctor. Keep your monitoring appointments. There is no pharmacologic reason to avoid this combination.